SLC13A5 and metabolic dysfunction-associated steatotic liver disease: Deletion of mIndy has previously been shown to improve metabolic disease, such as diet-induced obesity, insulin resistance, and nonalcoholic fatty liver disease in mice (5, 8, 9, 22).